3 years ago

EnsiliTech Raises £1.2 Million for 'Fridgeless' Vaccine Technology

  • EnsiliTech, a Bath-based biotech spinout, has secured £1.2 million in pre-seed funding for its “fridgeless” technology that keeps vaccines at the right temperature during transportation

  • The technology uses silica to protect the active ingredients of vaccines, allowing them to be transported at temperatures between -20C to 80C

  • This eliminates the need for refrigeration and reduces vaccine waste during transportation

  • The funding was led by Science Angel Syndicate and the Fink Family Office, with support from QantX, Elbow Beach Capital, Innovate UK, and angel investors.

      • ProblemHealthcare

      "Maintaining the cold chain for vaccine distribution is expensive, wasteful, and limits vaccine access in remote areas."

      Solution

      "EnsiliTech's ensilication technology creates a protective layer around vaccines, allowing them to be stored and transported at a wider temperature range (-20C to 80C), eliminating the need for constant refrigeration."

      Covered on